Krystal Biotech pre-announces 2025 VYJUVEK revenue ~$388-389M; outlines 4 product launches by 2030

Krystal Biotech, Inc.

2025-FY EPS reported $6.84 revenue$389,130,000

Preliminary Q4 2025 VYJUVEK net revenue $106-107M; full year $388-389M.
Cash, equivalents and investments ~$955M as of Dec 31, 2025.
Targets 4 marketed rare-disease medicines (incl. VYJUVEK) by end of 2030, treating >10,000 patients.
2026 combined non-GAAP R&D and SG&A expense guidance $175-195M (excl. stock comp).
Pipeline milestones: Phase 3 data for KB803 (ocular DEB) and KB801 (NK) in 2026; KB407 CF study enrollment starts.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.